Trump Administration's Efforts to Lower U.S. Drug Prices

Americans face some of the highest prescription drug prices globally, with costs nearly three times higher than the average in 33 other wealthy countries, according to Rand Health Care. In 2024, total pharmaceutical expenditures in the U.S. reached $805.9 billion, with patients directly paying about 13% out of pocket. High drug prices contribute to increased insurance premiums and taxes, affecting programs like Medicare and Medicaid, which serve millions of Americans.

CityLabHealthCareDiveReuters

In response to this crisis, President Donald Trump has pledged to reduce drug prices, aiming to align them with those in other affluent nations. Following an executive order in May 2023, Trump directed drug manufacturers to voluntarily match U.S. prices to the "most favored nation" price, the lowest price paid by similar countries. In July 2023, he sent letters to 17 major drugmakers, urging them to offer these prices for new drugs and facilitate direct consumer purchases.

CityLab

Since then, several companies, including Pfizer, AstraZeneca, and Eli Lilly, have agreed to price cuts for certain medications. For instance, Eli Lilly and Novo Nordisk have committed to providing their GLP-1 obesity drugs to Medicare patients for $245 per month, a significant reduction from previous prices.

CityLab

The Centers for Medicare & Medicaid Services (CMS) is also taking steps to lower drug spending in Medicaid through a new voluntary payment model called GENEROUS, set to launch in January 2026. This model will negotiate prices based on select international data, aiming to reduce Medicaid spending, which exceeded $100 billion in 2024.

HealthCareDiveCityLab

Despite these initiatives, the pharmaceutical industry has expressed concerns. The Pharmaceutical Research and Manufacturers of America (PhRMA) argues that linking U.S. prices to foreign rates could undermine American innovation and leadership in biomedical research. Critics of the current pricing system highlight the substantial profit margins of drug companies, pointing to discrepancies between production costs and retail prices. For example, Novo Nordisk reportedly produces its diabetes treatment Ozempic for less than $5, while charging nearly $1,000 in the U.S.

CityLab

While the Trump administration's agreements with drugmakers are expected to provide some relief, the long-term impact remains uncertain. Questions persist about the depth of price cuts for Medicaid and the effectiveness of direct-to-consumer sales. The TrumpRx platform, intended to connect patients with lower prices, is anticipated to launch in 2026, but it is unclear how many Americans will utilize it given that most have insurance covering part of their drug costs.

CityLab

• “Drug prices in the U.S. remain far too high,” — Abe Sutton, Director, Center for Medicare and Medicaid Innovation

HealthCareDive

• “Importing foreign price controls would undermine American leadership, hurting patients and workers,” — Alex Schriver, Spokesman, PhRMA

CityLab

• “When monthly costs fall below $200, access to evidence-based treatment expands dramatically,” — Dr. Leslie Golden, Obesity Medicine Physician

Reuters

The ongoing efforts by the Trump administration to reform drug pricing highlight a critical intersection of healthcare policy and economic strategy, with significant implications for millions of Americans reliant on affordable medications.

CityLab